Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 2

Conditions

Keratosis, Actinic 2Keratosis 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × tirbanibulin × Dermatologic × Clear all
NCT05741294 2025-02-20

A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

Almirall, S.A.

Phase 4 Completed
334 enrolled 12 charts
Dermatologic

Keratosis, Keratosis, Actinic

NCT05260073 2024-09-20

PROAK

Almirall, S.A.

Completed
300 enrolled 9 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡